Navigation Links
Ironwood and Forest to Present Additional Phase 2b Data for Novel Gastrointestinal Agent Linaclotide
Date:5/12/2009

Jeffrey Johnston, M.D., F.A.C.P., F.A.C.G. on Tuesday, June 2 from 8:00 a.m. to 5:00 p.m.

About Linaclotide

Linaclotide is a first-in-class compound in Phase 3 clinical development for the treatment of IBS-C and CC. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide significantly reduced abdominal pain and bloating and improved bowel function throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week treatment period. Across both studies, the most common adverse event in the linaclotide-treated groups was diarrhea. The discontinuation rate due to any adverse event was 4.7 percent. Linaclotide is a once daily, orally delivered peptide that acts locally in the gut with no detectable systemic exposure at therapeutic doses. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. An issued composition of matter patent for linaclotide provides protection to 2025. In September 2007, Ironwood and Forest entered into a 50/50 collaboration to co-develop and co-promote linaclotide in United States.

About Irritable Bowel Syndrome with Constipation (IBS-C)

IBS-C is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits. There are currently few available therapies to treat this disorder. Nine million U.S. patients have been diagnosed with IBS-C, and as many as 15 million people in the U.S. suffer from it. Patients suffering from IBS-C can be affected physically, psychologically, socially, and economically.

About Chronic Constipation (CC)

As many as 23 million Americans suffer from CC and 12 million patien
'/>"/>

SOURCE Forest Laboratories, Inc.; Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Video: NASONEX(R) (Mometasone Furoate Monohydrate) Nasal Spray, 50 mcg* Teams Up With American Forests to Educate Nasal Allergy Sufferers and Help Improve Air Quality
2. Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorneys Office Investigation
3. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
5. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
6. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
7. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
8. Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video
9. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
10. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
11. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... According to a recent report by the U.S. ... deaths more than tripled in the same period—leading a majority of law enforcement agencies ... , a leading Florida-based drug treatment facility, asserts that these heroin statistics point to ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Broadway by ... which features multiple patient and family member testimonials. Medicare rated the care center as ... plans to use the video to give future patients a firsthand look at the ...
(Date:6/30/2015)... ... June 30, 2015 , ... From the moment a patient ... with the incredible care that they receive and the luxury in which they are ... now they are proud to offer the same experience, just better! , Their office ...
(Date:6/30/2015)... ... June 30, 2015 , ... MJH Associates ... HRA Healthcare Research & Analytics , a consultative healthcare market research practice that ... of businesses. HRA offers quantitative and qualitative, custom and multi-client primary market research ...
(Date:6/30/2015)... ... ... Independence Day weekend is more than just fireworks to celebrate America’s birthday, it’s ... National Hot Dog Month. Americans are expected to eat more than 150 million hot ... enough to stretch from Washington D.C. to Los Angeles more than five times. , ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 2Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 3Health News:NJ Top Dentist, Dr. Laurence C. Breiterman is Now Offering the WOW Factor at His Highly Regarded Dental Practice 4Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 2Health News:HRA Healthcare Research & Analytics Welcomes 'Creative Problem Solver' as New Executive Vice President 3Health News:Biggest Hot Dog Weekend of the Year to Kick Off National Hot Dog Month 2
... WEDNESDAY, Jan. 19 (HealthDay News) -- Intensive care patients ... are resistant to many drugs may be more likely ... new study suggests. The findings highlight the need ... Infectious Diseases Society of America (IDSA) guidelines, said the ...
... WEDNESDAY, Jan. 19 (HealthDay News) -- Nearly 42 percent ... end-of-life care services -- such as massages or ... alternative service provider, according to the latest data. ... and Prevention,s National Center for Health Statistics, concerns what ...
... hemorrhagic fever in humans, has no known cure or vaccine. ... scientists has uncovered a family of small molecules which appear ... inhibit its entry into human cells. The results are ... and are now online. Previous studies have shown ...
... DNA determine the outcome and success in patients who ... complications? The National Heart, Blood and Lung Institute of ... million, four-year grant to Fred Hutchinson Cancer Research Center ... of the Hutchinson Center,s Clinical Research Division and medical ...
... bin Zayed Al Nahyan Charity Foundation is granting $150 ... Center to support genetic-analysis based research, diagnosis and treatment ... Nahyan, Deputy Prime Minister, Minister of Presidential Affairs and ... Chancellor of The University of Texas System, recently witnessed ...
... online, open access, primary research journal for authors in all ... itself, PRX will publish original, high quality, scientifically sound research ... global multidisciplinary readership. PRX will provide validation through prompt and ... with the strong reputation of the Physical Review ...
Cached Medicine News:Health News:Study Questions Safety of Pneumonia Treatment Guidelines 2Health News:Many U.S. Hospices Provide Alternative Therapies: Report 2Health News:Small molecules may prevent ebola infection 2Health News:Does our DNA determine how well we respond to stem-cell transplantation? 2Health News:Khalifa Foundation grants MD Anderson $150 million for cancer research 2Health News:American Physical Society announces Physical Review X 2
(Date:6/30/2015)... Calif. , June 30, 2015  Ardelyx, Inc. ... on cardio-renal, gastrointestinal and metabolic diseases, today announced that ... July 14, 2015, from 8:00 a.m.- 1:00 pm EDT ... The Ardelyx senior management team will present ... lead compound, tenapanor, which has completed Phase 2b clinical ...
(Date:6/30/2015)... , BERKELEY, Kalifornien, und KOPENHAGEN, Dänemark, ... Biologics, Inc. , ein Weltmarktführer der klinischen ... anderen therapeutischen Proteinen, gab heute bekannt, dass ... der Produktionskapazität den Ausbau der nordamerikanischen Produktionsanlage ... mit der Ergänzung  einer Einweg-Anlage Bioreactor 6Pack™ ...
(Date:6/30/2015)... , June 24, 2015 Research ... of the "Global Endoscopy Devices Market 2015-2019" ... global endoscopy devices market to grow at a ... The global endoscopy devices market can be segmented ... accessories, and services. The market can be further ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 2Global Endoscopy Devices Market 2015-2019 - Key Players are Boston Scientific, Johnson and Johnson, Medtronic, Karl Storz & Olympus 3
... (Nasdaq: ISIS ), the leader in antisense therapeutics, ... Stifel Nicolaus, Healthcare Conference 2011 on Thursday, September 08, 2011 ... Boston. A live audio webcast of the presentation ... the Company,s Web site, www.isispharm.com .  A replay of ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... Company,s participation at the William Blair and Company 5th Annual ... Hotel in New York City on September 8, 2011. ... Research and Development, will present on Thursday, September 8, 2011 ...
Cached Medicine Technology:Sequenom Announces Participation at William Blair and Company 5th Annual Emerging Growth Stock Conference 2
... If you prefer a standard ... the Volk Iridectomy Lens. Its ... view you're used to but ... Volk's exclusive Double Aspheric design ...
... 2.2 offers extremely high resolution treatment capability ... an exceptionally wide 78° field of view. ... critical evaluation of the optic nerve head ... of the macula and disc. Redesigned to ...
... for focal laser therapy and mid-to-far peripheral ... a realistic contour of the retinal concavity, ... entire posterior pole extending to the equator. ... dynamic movement on the globe, therefore increasing ...
... The Digital 1.0x Imaging Lens is optimized ... reduce glare and reflections during general diagnosis and ... view of the posterior pole and a sharper ... Digital 1.0 X Imaging Lens is also ideal ...
Medicine Products: